Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 2Phase NA 1Phase EARLY_PHASE1 1Phase 2/3 1Phase 1 1

Status

Terminated 2Recruiting 2Completed 2Withdrawn 1Not yet recruiting 1

Sponsor Class

OTHER_GOV 1OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 1

Conditions

Neoplasms, Germ Cell and Embryonal 1Melanoma 1

Interventions

Cyclophosphamide 739Cisplatin 687Gemcitabine 641Bevacizumab 615Carboplatin 604Paclitaxel 600Docetaxel 565Radiotherapy 536Fluorouracil 405Oxaliplatin 387Rituximab 369Doxorubicin 360Capecitabine 342Filgrastim 333Etoposide 328Dexamethasone 312Irinotecan 309pembrolizumab 279Leucovorin 274Cetuximab 267Cytarabine 242Erlotinib Hydrochloride 231Prednisone 227Nivolumab 227Trastuzumab 225Bortezomib 221Vincristine 220Methotrexate 207Pemetrexed 199fludarabine phosphate 195

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Completed × Disulfiram × Clear all
NCT02101008 2023-12-13

Disulfiram and Chelated Zinc for the Rx of Disseminated Mets Mel That Has Failed First Line Therapy

University of Utah

Phase 2 Completed
12 enrolled 6 charts
Dermatologic

Melanoma

NCT03950830 2023-10-04

DISGCT

National Cancer Institute, Slovakia

Phase 2 Completed
12 enrolled

Neoplasms, Germ Cell and Embryonal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡